-

Syntax Bio to Present New Cellgorithm™ Research at ISSCR iPSC 20th Anniversary Symposium in Kyoto

CHICAGO--(BUSINESS WIRE)--Syntax Bio will present new research on its Cellgorithm™ cell-programming platform at the International Society for Stem Cell Research (ISSCR) iPSC 20th Anniversary Symposium, held Oct. 20-22 at the Kyoto International Conference Center in Kyoto, Japan.

Syntax Bio will present new Cellgorithm research at ISSCR’s Kyoto symposium, showing human stem cells guided toward pancreatic beta cell states in just four days.

Share

The research showed that Cellgorithm differentiated human induced pluripotent stem cells (iPSC) toward pancreatic beta cell states in four days. The study also identified genetic 'gridlocks' that stall cells at intermediate stages of development.

The findings could support more precise control over stem cell programming and faster, more reliable and scalable production of specialized cells for therapeutic use.

Syntax Bio co-founder and chief scientific officer Ryan Clarke, PhD, and chief executive officer John Craighead, PhD, will be available in Kyoto to discuss the findings and their implications for cell therapy development. To schedule an interview, contact Matt Burns.

Oral Presentation

Title: Cellgorithms: Programming Human iPSC Differentiation With Modular, Time-Resolved CRISPRa Cascades
Presenter: Ryan Clarke, PhD, co-founder and chief scientific officer, Syntax Bio
Date and time: Oct. 21, 2026, 10:10-10:30 a.m. Japan Standard Time (UTC+9)
Location: Event Hall

Poster Presentation

Title: Cellgorithms: Programming Human iPSC Differentiation with Modular, Time-Resolved CRISPRa Cascades
Presenter: Ryan Clarke, PhD, co-founder and chief scientific officer, Syntax Bio
Poster number: 288
Date and time: Oct. 21, 2026, 6:00-6:45 p.m. Japan Standard Time (UTC+9)
Location: New Hall

About Syntax Bio

Syntax Bio is a synthetic biology company programming the next generation of regenerative medicines. Its proprietary Cellgorithm™ platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how cell therapies are discovered, developed and manufactured. By replacing slow, labor-intensive differentiation processes with a rapid, programmable approach that mimics human development, Syntax Bio can generate specialized cells in days or weeks rather than months, more reliably and at scale, unlocking new possibilities across the biotechnology industry. Learn more at syntax-bio.com.

Contacts

Media Contact:
Matt Burns
Acumen Strategies
matt@acumen-strategies.com
518-423-5907

Syntax Bio


Release Versions

Contacts

Media Contact:
Matt Burns
Acumen Strategies
matt@acumen-strategies.com
518-423-5907

Social Media Profiles
More News From Syntax Bio

Syntax Bio and Applied StemCell Announce Strategic Collaboration to Advance Stem Cell Innovation

CHICAGO & MILPITAS, Calif.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, today announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC’s iPSC and hypoimmune cell lines using Syntax Bio’s proprietary Cellgorithm™ platform to advanc...

Syntax Bio, Ajinomoto Health & Nutrition North America, Inc. Collaborate to Evaluate Stem Cell Culture Technologies Using Cellgorithm™ Platform

CHICAGO & ITASCA, Ill.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Ajinomoto Health & Nutrition North America, Inc. (AHN), a leader in amino acid science and cell culture innovation and part of Ajinomoto Group, today announced a collaboration to evaluate Ajinomoto Group’s StemFit™ stem cell culture products using Syntax Bio’s proprietary Cellgorithm™ platform. Through the collaboration, AHN is providing Syntax Bio with Ste...

Syntax Bio Announces Expanded Series A and Leadership Appointments

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million. The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansu...
Back to Newsroom